JP2002308895A5 - - Google Patents

Download PDF

Info

Publication number
JP2002308895A5
JP2002308895A5 JP2002026232A JP2002026232A JP2002308895A5 JP 2002308895 A5 JP2002308895 A5 JP 2002308895A5 JP 2002026232 A JP2002026232 A JP 2002026232A JP 2002026232 A JP2002026232 A JP 2002026232A JP 2002308895 A5 JP2002308895 A5 JP 2002308895A5
Authority
JP
Japan
Prior art keywords
angstroms
rays
irradiation
wavelength
copper
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002026232A
Other languages
English (en)
Japanese (ja)
Other versions
JP3748536B2 (ja
JP2002308895A (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2002026232A priority Critical patent/JP3748536B2/ja
Priority claimed from JP2002026232A external-priority patent/JP3748536B2/ja
Publication of JP2002308895A publication Critical patent/JP2002308895A/ja
Priority to US10/637,300 priority patent/US6908906B2/en
Publication of JP2002308895A5 publication Critical patent/JP2002308895A5/ja
Application granted granted Critical
Publication of JP3748536B2 publication Critical patent/JP3748536B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2002026232A 2001-02-09 2002-02-04 ピリミジンヌクレオシド誘導体の結晶 Expired - Lifetime JP3748536B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2002026232A JP3748536B2 (ja) 2001-02-09 2002-02-04 ピリミジンヌクレオシド誘導体の結晶
US10/637,300 US6908906B2 (en) 2001-02-09 2003-08-07 Crystalline forms of pyrimidine nucleoside derivative

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001-33128 2001-02-09
JP2001033128 2001-02-09
JP2002026232A JP3748536B2 (ja) 2001-02-09 2002-02-04 ピリミジンヌクレオシド誘導体の結晶

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2005230800A Division JP4356998B2 (ja) 2001-02-09 2005-08-09 ピリミジンヌクレオシド誘導体の結晶を含有する医薬

Publications (3)

Publication Number Publication Date
JP2002308895A JP2002308895A (ja) 2002-10-23
JP2002308895A5 true JP2002308895A5 (https=) 2005-08-18
JP3748536B2 JP3748536B2 (ja) 2006-02-22

Family

ID=18896929

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002026232A Expired - Lifetime JP3748536B2 (ja) 2001-02-09 2002-02-04 ピリミジンヌクレオシド誘導体の結晶
JP2005230800A Expired - Lifetime JP4356998B2 (ja) 2001-02-09 2005-08-09 ピリミジンヌクレオシド誘導体の結晶を含有する医薬

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2005230800A Expired - Lifetime JP4356998B2 (ja) 2001-02-09 2005-08-09 ピリミジンヌクレオシド誘導体の結晶を含有する医薬

Country Status (21)

Country Link
EP (1) EP1364959B1 (https=)
JP (2) JP3748536B2 (https=)
KR (1) KR100679904B1 (https=)
CN (1) CN100408591C (https=)
AT (1) ATE361929T1 (https=)
AU (1) AU2002230164B2 (https=)
BR (2) BR0207102A (https=)
CA (1) CA2437994C (https=)
CY (1) CY1106685T1 (https=)
CZ (1) CZ303241B6 (https=)
DE (1) DE60220024T2 (https=)
DK (1) DK1364959T3 (https=)
ES (1) ES2286237T3 (https=)
HU (1) HU229294B1 (https=)
IL (2) IL157216A0 (https=)
MX (1) MXPA03007123A (https=)
NZ (1) NZ527393A (https=)
PT (1) PT1364959E (https=)
RU (1) RU2256666C2 (https=)
WO (1) WO2002064609A1 (https=)
ZA (1) ZA200306121B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2265101B1 (en) 1999-09-02 2012-08-29 Ibiden Co., Ltd. Printed circuit board and method of manufacturing printed circuit board
US6876554B1 (en) 1999-09-02 2005-04-05 Ibiden Co., Ltd. Printing wiring board and method of producing the same and capacitor to be contained in printed wiring board
GB0526419D0 (en) * 2005-12-23 2006-02-08 Cyclacel Ltd Formulation
GB0625283D0 (en) 2006-12-19 2007-01-24 Cyclacel Ltd Combination
JP5066737B2 (ja) * 2007-04-06 2012-11-07 大鵬薬品工業株式会社 シチジン誘導体を含有する持続静脈内投与用抗腫瘍剤
US8124593B2 (en) 2007-11-05 2012-02-28 Cyclacel Limited Methods of treatment using sapacitabine
GB0808357D0 (en) * 2008-05-08 2008-06-18 Cyclacel Ltd Process
NZ589719A (en) 2008-06-09 2012-08-31 Cyclacel Ltd Combinations of sapacitabine or cndac with dna methyltransferase inhibitors such as decitabine and procaine
HUE046177T2 (hu) 2011-04-14 2020-02-28 Cyclacel Ltd Szapacitabin és decitabin kombinációjának adagolási rendje akut mieloid leukémia kezelésére
KR102081042B1 (ko) * 2012-03-15 2020-02-26 셀젠 카르 엘엘씨 상피 성장 인자 수용체 키나제 억제제의 고체 형태
EP3268379B1 (en) 2015-03-09 2023-11-01 W.R. Grace & CO. - CONN. Crystalline form of nicotinamide riboside
CN112020363A (zh) 2017-12-22 2020-12-01 益力舒健康公司 烟酰胺核苷氯化物的结晶形式

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2559917B2 (ja) * 1990-06-15 1996-12-04 三共株式会社 ピリミジンヌクレオシド誘導体
RU2085557C1 (ru) * 1991-09-30 1997-07-27 Санкио Компани Лимитед Производные нуклеозидов пиримидина или их фармацевтически приемлемые соли и способ их получения

Similar Documents

Publication Publication Date Title
JP2023145481A5 (https=)
JP2002308895A5 (https=)
JP2011168587A5 (https=)
AR029570A1 (es) Nueva forma cristalina gamma de la sal de terbutilamina de perindopril, procedimiento para su preparacion y composiciones farmaceuticas que la contienen
JP2020511467A5 (https=)
DE60325074D1 (de) Kristall für ein orales, festes arzneimittel, und ein orales, festes arnzeimittel zur behandlung von dysurie, das diesen enthält
WO2004004648A3 (en) Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
CA2415438A1 (fr) Forme cristalline .alpha. du sel de tert-butylamine du perindopril
JP2008506632A5 (https=)
ATE545630T1 (de) Kristallform des kaliumsalzes von (2r,4r)-monatin und diese enthaltende süssmittelzusammensetzung
KR970027079A (ko) (r)-(-)-2-{n-[4-(1,1-디옥시도-3-옥소-2,3-디히드로-벤즈이소티아졸-2-일)-부틸]-아미노메틸}-크로만의 결정성 염산염
IS7965A (is) Þíenópýrimidíndíón og notkun þeirra í breytingu ásjálfsnæmissjúkdómi
AR029571A1 (es) Nueva forma cristalina beta de la sal de terbutilamina de perindopril, procedimiento para su preparacion y composiciones farmaceuticas que la contienen
UA83720C2 (ru) Кристаллическая форма v агомелатина, способ ее получения и фармацевтическая композиция, которая ее содержит
TNSN07165A1 (en) Organic compounds
JP2007191765A5 (https=)
JP2004510683A5 (https=)
JP2006502115A5 (https=)
JP2004517961A5 (https=)
CU23200A3 (es) Sal polimorfica
CA2437994A1 (en) Crystalline forms of pyrimidine nucleoside derivative
JP2016172741A5 (https=)
JPWO2020179781A5 (https=)
TW200509906A (en) Crystalline 1-methylcarbapenem compounds
CL2004000856A1 (es) Compuestos derivados 8b-vonil-11b-(alfa-sustituidos)alquil-estra-1,3,5(10)-trienos; composiciones farmaceuticas; compuestos intermediarios; uso para la anticoncepcion, para el tratamiento de carcinomas de ovario y tumores de celulas granulosas.